Aberrant Activation of Epidermal Growth Factor ...

52 downloads 139 Views 273KB Size Report
Aberrant Activation of Epidermal Growth Factor Receptor in MPN May. Respond to the Kinase Inhibitor Gefitinib. Introduction. Results. Conclusions. References.
Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib Casolari DA1,2,3*, Iarossi DG1,2,3*, Butcher CM1*, Bray SC1,2,3,4*, Parker WT2,3,5*, Nguyen T1,2,3, Hahn CN2,5*, Branford S2,3,5,6,7, Bardy P8*, Lewis ID2,9, Scott HS2,5,6,7*, Lane SW10, Ross DM9* and D'Andrea RJ1,2,3,7 1Department

of Haematology, SA Pathology; 2Centre for Cancer Biology, SA Pathology and University of South Australia; 3School of Pharmacy and Medical Sciences, University of South Australia; 4Discipline of Medicine, University of Adelaide; 5Department of Genetics and Molecular Pathology, SA Pathology; 6School of Molecular and Biomedical Science, University of Adelaide; 7School of Medicine, University of Adelaide; 8Haematology/Oncology, The Queen Elizabeth Hospital; 9Department of Haematology, SA Pathology and the Royal Adelaide Hospital; 10Department of Immunology, QIMR Berghofer Medical Research Institute, Australia

 Only cells expressing high levels of either wild type or mutant receptor are able to grow in the absence of mIL3

70 60 50 40 30 20 10 0

EGFRC329R does not confer proliferation advantage, compared to the WT receptor

Results

0

1

2 Days BaF3/EGFR IL3 ind BaF3/EGFRC329R IL3 ind

3

4

EC50(ng/ml) p